Infection Prophylaxis in Urological Diagnostic and Surgical Procedures - A narrative review and recommendations.

Objectives: In this review we will provide recommendations for surgical site infection (SSI) prophylaxis in urological diagnostic and surgical procedures.

Material And Methods: We performed a narrative review of the literature in PubMed (Medline), EMBASE, LILACS, Web of Science, and Cochrane Collaboration databases using the terms "infection," "surgery," "urology," and "antibiotic prophylaxis" Results: We suggest recommendations of prophylactic antibiotic in the follow procedures: prostate biopsy, Urethrocystoscopy, Extracorporeal Shock Wave Lithotripsy (ESWL) for Urinary Stones, endoscopic ureterolithotripsy, percutaneous nephrolitothomy, Transurethral Resection of the Prostate (TURP) and Prostatic Enucleation, Transurethral Resection of Bladder Tumor (TURBT), Intravesical Botulinum Toxin Injection, surgical correction of female stress incontinence, Surgical Correction of Pelvic Organ Prolapse, urological prosthesis implantation and Open, Laparoscopic, and Robotic Urologic Surgery Conclusions: Consideration in SSI prophylaxis and the prophylactic antibiotic regimens in several urological procedures are show in this paper and will be useful to urologic practice.

Daily use of phosphodiesterase type 5 inhibitors as prevention for recurrent priapism.

Objective: The pathogenesis of recurrent priapism is currently being investigated based on the regulation of the phosphodiesterase 5 (PDE5) enzyme. We explored the daily use of PDE5 inhibitors to treat and prevent priapism recurrences.

Method: We administered PDE5 inhibitors using a long-term therapeutic regimen in seven men with recurrent priapism, with a mean age of 29.

Sustained nitric oxide (NO)-releasing compound reverses dysregulated NO signal transduction in priapism.

We evaluated the therapeutic potential of a sustained nitric oxide (NO)-releasing compound to correct the molecular hallmarks and pathophysiology of priapism, an important but poorly characterized erectile disorder. 1,5-Bis-(dihexyl-N-nitrosoamino)-2,4-dinitrobenzene (C6') and an inactive form of the compound [1,5-bis-(dihexylamino)-2,4-dinitrobenzene (C6)] were tested in neuronal cell cultures and penile lysates for NO release (Griess assay) and biological activity (cGMP production). The effect of local depot C6' or C6 was evaluated in mice with a priapic phenotype due to double neuronal and endothelial NO synthase deletion (dNOS(-/-)) or human sickle hemoglobin transgenic expression (Sickle).

Fibrotic protein expression profiles in penile tissue of patients with erectile dysfunction.

Objective: To characterize transforming growth factor beta 1 (TGFβ1) and related signaling pathway proteins in a large cohort of human penile tissue (HPT) samples.

Methods: HPT was collected from patients undergoing penile prosthesis implantation for erectile dysfunction (ED) and divided into the following 2 groups: postradical prostatectomy ED (RP-ED; n = 57) and organic ED (O-ED; n = 30). HPT from patients undergoing partial penectomy without ED was used as controls (CON; n = 6).

Molecular analysis of erection regulatory factors in sickle cell disease associated priapism in the human penis.

Purpose: Priapism is a vasculopathy that occurs in approximately 40% of patients with sickle cell disease. Mouse models suggest that dysregulated nitric oxide synthase and RhoA/ROCK signaling as well as increased oxidative stress may contribute to the mechanisms of sickle cell disease associated priapism. We examined changes in the protein expression of nitric oxide synthase and ROCK signaling pathways, and a source of oxidative stress, NADPH oxidase, in penile erectile tissue from patients with a priapism history etiologically related and unrelated to sickle cell disease.